Drug Type γ-δT |
Synonyms LB 2103, LB2103 |
Target |
Action modulators |
Mechanism BCMA modulators(B-cell maturation protein modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Multiple Myeloma | Preclinical | United States | 03 Oct 2022 |





